despit
improv
lung
function
nutrit
outcom
individu
cystic
fibrosi
cf
past
decad
pulmonari
exacerb
pex
remain
common
accord
us
cystic
fibrosi
foundat
patient
registri
data
one
three
patient
requir
least
one
cours
intraven
iv
antibiot
treat
pex
exacerb
profound
impact
morbid
qualiti
life
individu
cf
unfortun
pex
outcom
remain
suboptim
poor
recoveri
baselin
lung
function
follow
pex
treatment
result
effort
way
within
cf
research
commun
improv
manag
clinic
impact
event
focu
review
summar
recent
advanc
taken
place
understand
epidemiolog
pathophysiolog
diagnosi
manag
pex
cf
provid
direct
futur
studi
although
gener
agreement
import
pex
consensu
definit
constitut
pex
cf
clinician
research
broader
cf
commun
howev
ideal
consensu
pex
definit
score
system
like
remain
elus
without
gold
standard
compar
vari
pex
definit
employ
cf
literatur
major
impedi
research
progress
inher
confound
mani
studi
includ
review
caveat
must
kept
mind
read
review
potenti
lack
specif
studi
discuss
attempt
move
toward
consensu
pex
definit
eurocfcar
work
group
recommend
use
modifi
fuch
criteria
defin
pex
includ
need
addit
antibiot
treatment
oral
iv
recent
chang
least
two
follow
six
criteria
chang
sputum
volum
color
increas
cough
increas
fatigu
malais
lethargi
anorexia
weight
loss
decreas
pulmonari
function
radiograph
chang
increas
dyspnea
howev
definit
critic
expert
field
diagnosi
pex
independ
physician
decis
treat
pulmonari
function
test
limit
age
rang
patient
assess
recent
pediatr
trial
use
pex
definit
employ
earli
pseudomona
infect
control
epic
trial
consist
one
major
criterion
decreas
forc
expiratori
volum
one
second
fev
least
baselin
previou
month
oxygen
satur
less
room
air
least
declin
baselin
new
lobar
infiltr
atelectasi
chest
xray
hemoptysi
two
minor
symptomssign
increas
respiratori
rate
new
increas
adventiti
sound
lung
exam
weight
loss
least
previou
month
increas
cough
decreas
exercis
toler
increas
chest
congest
chang
sputum
least
day
signific
symptom
sever
despit
lack
consensu
pex
definit
recent
studi
focus
strategi
diagnos
cf
pex
earlier
given
risk
poor
outcom
standard
treatment
pulmonari
exacerb
stop
studi
multisit
observ
studi
patient
cf
treat
iv
antibiot
hospit
patient
describ
symptom
day
admiss
nearli
onethird
symptom
day
beforehand
less
half
individu
receiv
oral
antibiot
prior
admiss
suggest
certain
patient
may
prolong
symptom
keep
pex
due
delay
diagnosi
start
treatment
reason
recent
focu
home
monitor
symptom
lung
function
promot
earlier
pex
detect
treatment
prevent
irrevers
lung
damag
multicent
studi
netherland
examin
electron
home
monitor
symptom
lung
function
earli
pex
detect
confirm
chang
symptom
least
week
prior
pex
diagnosi
patient
symptom
deterior
week
prior
pex
diagnosi
howev
larg
multicent
random
trial
recent
conduct
us
demonstr
although
electron
home
monitor
symptom
spirometri
feasibl
lead
earlier
frequent
diagnos
pex
compar
usual
care
strategi
lead
less
lung
function
lost
year
earlier
diagnosi
homemonitor
arm
led
frequent
use
oral
versu
iv
antibiot
compar
usualcar
arm
versu
might
result
higher
rate
nonrecoveri
fev
predict
within
baselin
versu
due
less
robust
respons
oral
antibiot
treatment
author
conclud
identifi
pex
earlier
may
suffici
futur
studi
must
also
find
better
approach
treatment
exacerb
detect
howev
may
still
util
home
monitor
earli
pex
detect
particularli
individu
poor
perceiv
symptom
frequent
exacerb
resid
rural
area
may
delay
access
care
proport
patient
requir
least
one
cours
iv
antibiot
per
year
decreas
significantli
past
decad
although
might
seem
concern
light
overal
improv
lung
function
observ
time
period
appear
driven
lower
threshold
among
clinician
diagnos
treat
pex
import
studi
highlight
wide
variabl
recognit
treatment
pex
cf
clinic
individu
cf
physician
us
uk
multicent
studi
uk
demonstr
higher
iv
antibiot
use
among
center
higher
baselin
fev
predict
wherea
older
multicent
us
studi
found
variabl
among
center
respect
care
higher
median
fev
predict
frequent
monitor
antibiot
find
led
qualiti
improv
initi
reduc
variabl
order
prevent
pex
associ
sequela
great
deal
interest
identifi
risk
factor
futur
pex
vandevant
et
al
investig
factor
associ
increas
risk
pex
requir
iv
antibiot
studi
found
numer
clinic
variabl
includ
sputum
microbiolog
treatment
characterist
strongest
risk
factor
pex
requir
iv
antibiot
therapi
occurr
pex
requir
iv
antibiot
preced
year
surprisingli
individu
three
exacerb
highest
risk
futur
pex
compar
one
two
exacerb
regard
pex
treatment
outcom
exacerb
treat
oral
antibiot
often
consid
milder
event
wherea
treat
iv
antibiot
consid
repres
sever
event
howev
label
pex
basi
rout
antibiot
treatment
oral
versu
iv
limit
potenti
bias
sinc
factor
pex
sever
base
symptom
inflammatori
marker
lung
function
declin
combin
may
influenc
decis
antibiot
rout
instanc
iv
antibiot
may
chosen
basi
medic
allergiesintoler
bacteri
resist
oral
antibiot
nondiseas
severityrel
factor
psychosoci
issu
insur
coverag
support
concept
exacerb
treat
oral
antibiot
may
repres
mild
event
base
recent
retrospect
studi
use
toronto
cf
databas
nearli
exacerb
treat
oral
antibiot
recov
within
baselin
fev
predict
within
month
treatment
furthermor
greater
number
cumul
oral
antibiotictr
event
studi
period
steeper
rate
lung
function
declin
consequ
close
followup
posttreat
warrant
ensur
recoveri
patient
repeat
exacerb
treat
oral
antibiot
may
warrant
intens
treatment
iv
antibiot
even
among
patient
receiv
aggress
treatment
iv
antibiot
pex
outcom
remain
suboptim
base
cf
registri
data
us
canada
individu
experi
exacerb
fail
recov
baselin
lung
function
defin
baselin
within
month
treatment
factor
independ
associ
nonrespons
includ
femal
sex
malnourish
pancreat
insuffici
persist
infect
pseudomona
aeruginosa
burkholderia
cepacia
complex
methicillinresist
staphylococcu
aureu
allerg
bronchopulmonari
aspergillosi
larger
drop
fev
predict
time
pex
longer
time
baselin
spirometr
assess
import
recogn
proport
nonrespond
vari
substanti
depend
definit
respons
use
exampl
definit
fev
improv
baselin
employ
exacerb
classifi
nonrespond
wherea
improv
baselin
yield
nonrespons
rate
high
furthermor
note
patient
stop
trial
best
lung
function
time
pex
diagnosi
therefor
sizeabl
proport
patient
defin
respond
even
treatment
start
lead
underestim
treatment
nonrespons
studi
use
best
fev
month
follow
end
iv
antibiot
treatment
followup
fev
sinc
lung
function
improv
continu
follow
complet
iv
antibiot
therefor
endoftreat
valu
underestim
rate
respons
viral
respiratori
tract
infect
estim
associ
exacerb
might
explain
exacerb
frequent
winter
month
common
viral
pathogen
includ
rhinoviru
respiratori
syncyti
viru
rsv
children
parainfluenza
influenza
adenoviru
coronaviru
coxsackieechoviru
previous
hypothes
virus
could
increas
bacteri
densiti
chronic
colon
organ
howev
recent
studi
refut
demonstr
chang
p
aeruginosa
densiti
viral
versu
nonviralassoci
pex
interestingli
antivir
interferon
signal
respons
rsv
infect
capabl
induc
p
aeruginosa
biofilm
format
dysregul
iron
homeostasi
could
repres
put
mechan
viraltrigg
pex
warrant
studi
also
import
note
although
appear
strong
associ
virus
pex
necessarili
impli
causal
relationship
studi
demonstr
presenc
viru
even
patient
well
suggest
asymptomat
nasopharyng
carriag
nonviralassoci
exacerb
also
believ
result
increas
bacteri
densiti
chronic
primari
pathogen
recent
studi
challeng
dogma
multipl
studi
demonstr
signific
chang
bacteri
densiti
stabl
pex
state
although
decreas
bacteri
densiti
observ
follow
antimicrobi
treatment
effect
transient
poorli
predict
clinic
respons
research
shown
cf
airway
infect
polymicrobi
interact
microb
may
increas
decreas
pathogen
believ
expert
organ
anaerob
interact
primari
pathogen
enhanc
virul
without
chang
densiti
exampl
recent
studi
evalu
airway
bacteri
commun
rrna
sequenc
found
signific
differ
bacteri
commun
divers
densiti
pair
stabl
pex
sampl
chang
commun
structur
subgroup
patient
furthermor
absolut
rel
abund
gemella
spp
increas
major
sampl
stabl
pex
state
discrimin
health
statu
stabl
versu
pex
air
pollut
also
import
trigger
pex
semin
studi
link
us
cf
nation
registri
us
environment
protect
agenc
aerometr
inform
retriev
system
demonstr
signific
associ
annual
averag
exposur
particul
matter
risk
pex
recent
casecrossov
analysi
confirm
find
found
increas
exposur
particul
matter
less
mm
diamet
pm
nitrogen
dioxid
ozon
associ
increas
need
oral
iv
antibiot
pex
day
exposur
gener
goal
pex
treatment
improv
symptom
recov
lost
lung
function
base
stop
studi
physician
identifi
recoveri
lung
function
primari
object
treatment
exacerb
compar
improv
symptom
exacerb
consider
variabl
constitut
accept
threshold
fev
improv
antibiot
stop
base
stop
studi
mean
fev
improv
standard
deviat
sd
predict
end
iv
antibiot
treatment
sd
predict
day
patient
baselin
fev
predict
greater
increas
fev
predict
admiss
day
patient
baselin
fev
less
predict
versu
interestingli
discord
physician
treatment
target
term
lung
function
improv
evalu
treatment
success
base
stop
studi
clinician
deem
pex
treatment
success
although
patient
achiev
least
target
fev
end
iv
antibiot
therapi
treatment
endpoint
individu
patient
like
depend
primari
motiv
factor
treatment
stop
studi
signific
proport
patient
admit
iv
antibiot
despit
present
best
record
fev
predict
prior
month
case
symptom
primari
driver
treatment
symptom
resolut
would
appropri
endpoint
treatment
respons
gener
exacerb
like
defin
base
symptom
alon
children
compar
adult
drop
lung
function
may
like
occur
wide
use
daili
score
system
monitor
respiratoryinfecti
symptom
pex
treatment
cystic
fibrosi
respiratori
symptom
diari
chronic
respiratori
infect
symptom
score
cfrsdcriss
total
score
rang
decreas
consid
clinic
signific
base
stop
cfrsdcriss
decreas
confid
interv
patient
achiev
clinic
signific
improv
howev
note
cfrsdcriss
limit
use
evalu
research
set
accept
us
food
drug
administr
valid
endpoint
wherea
shortterm
goal
pex
treatment
recov
lost
lung
function
improv
symptom
longterm
treatment
goal
gener
prevent
recurr
event
reduc
rate
lung
function
declin
interestingli
recent
studi
found
symptom
improv
cfrsdcriss
score
respons
pex
treatment
poorli
predict
longterm
respons
term
recoveri
baselin
lung
function
month
time
next
iv
antibiot
howev
immedi
fev
respons
rel
improv
predict
recoveri
baselin
fev
month
synthes
evid
suggest
composit
outcom
includ
symptom
lung
function
improv
might
appropri
endpoint
prospect
studi
examin
pex
therapi
base
cystic
fibrosi
foundat
pex
treatment
guidelin
insuffici
evid
provid
recommend
number
decis
relat
pex
manag
includ
site
treatment
inpati
versu
outpati
antibiot
durat
use
adjunct
therapi
system
steroid
figur
sinc
public
observ
studi
provid
addit
insight
treatment
controversi
random
control
trial
rct
ongo
recent
complet
circumst
admiss
hospit
optim
pex
treatment
clearli
indic
hypoxia
complic
pneumothorax
comorbid
renal
failur
mani
situat
outpati
treatment
iv
antibiot
appear
reason
option
howev
decid
optim
treatment
set
import
factor
safeti
feasibl
also
whether
one
treatment
set
efficaci
one
small
random
twofactor
mixeddesign
compar
studi
involv
adult
cf
perform
show
similar
result
outcom
measur
home
hospit
treatment
owe
select
bia
result
larger
rct
two
treatment
set
may
generaliz
challeng
interpret
lack
blind
attrit
bia
high
rate
crossov
lack
standard
resourc
home
care
variou
care
center
small
singlecent
retrospect
studi
examin
pex
event
patient
compar
hospit
home
iv
therapi
baselin
characterist
two
group
similar
howev
hospit
group
greater
improv
lung
function
shorter
durat
therapi
recent
observ
studi
pediatr
cf
patient
epidemiolog
studi
cf
escf
acut
declin
lung
function
like
recov
within
baselin
fev
receiv
treatment
inpati
versu
outpati
howev
observ
studi
involv
treatment
often
confound
indic
bia
word
patient
randomli
assign
therefor
intens
treatment
standard
comparison
ultim
patient
hospit
might
receiv
intens
treatment
anoth
recent
studi
also
use
escf
employ
statist
approach
control
indic
bia
found
pex
greater
proport
day
treat
inpati
versu
outpati
iv
antibiot
like
lead
return
fev
predict
least
baselin
although
observ
studi
definit
like
residu
confound
benefit
inpati
pex
treatment
like
due
multipl
factor
iv
antibiot
alon
includ
improv
medic
adher
better
nutrit
realtim
adjust
adjunct
therapi
increas
airway
clearanc
treatment
increas
rest
ultim
decis
regard
treatment
site
made
base
care
consider
patient
factor
low
threshold
inpati
treatment
concern
patient
reliabl
adher
airway
clearanc
therapi
suffici
home
support
complex
iv
antibiot
regimen
histor
reason
cf
exacerb
typic
treat
day
base
stop
studi
mean
durat
treatment
sd
day
howev
patient
receiv
treatment
day
less
receiv
treatment
day
signific
differ
durat
individu
younger
year
old
versu
older
year
old
random
studi
examin
durat
iv
antibiot
provid
evidencebas
recommend
observ
studi
use
us
cf
foundat
patient
registri
found
fev
predict
plateau
day
treatment
durat
treatment
influenc
time
next
pex
recent
retrospect
data
benefit
prolong
antibiot
treatment
conflict
studi
use
toronto
cf
databas
found
improv
outcom
longer
treatment
durat
day
wherea
larger
studi
use
data
escf
find
signific
associ
treatment
durat
rate
recoveri
fev
predict
within
baselin
howev
observ
studi
treatment
set
interpret
limit
indic
bia
sinc
patient
factor
influenc
treatment
durat
patient
lower
lung
function
receiv
longer
treatment
cours
larg
multicent
studi
way
us
examin
iv
antibiot
durat
sinc
identifi
import
research
question
cf
physician
patientscaregiv
diverg
trial
design
use
randomli
assign
patient
versu
day
versu
day
iv
antibiot
depend
initi
symptom
lung
function
respons
day
recent
studi
evalu
inpati
pex
treatment
practic
pediatr
cf
patient
across
us
demonstr
wide
variabl
use
adjunct
treatment
includ
hyperton
salin
azithromycin
system
corticosteroid
sever
adjunct
therapi
treatment
cf
pex
recent
evalu
current
investig
adjunct
therapi
function
either
optim
airway
clearanc
reduc
airway
inflamm
although
nebul
hyperton
salin
well
establish
strategi
pex
prevent
recent
studi
adjunct
pex
treatment
rct
dentic
et
al
compar
pex
outcom
individu
randomli
assign
nebul
hyperton
salin
versu
tastemask
control
thrice
daili
major
patient
group
either
never
intermitt
use
hyperton
salin
prior
enrol
although
studi
meet
primari
endpoint
term
reduc
length
hospit
stay
greater
improv
symptom
higher
rate
fev
recoveri
hyperton
salin
group
furthermor
studi
provid
reassur
nebul
hyperton
salin
safe
start
increas
context
acut
pex
anoth
recent
studi
examin
doxycyclin
adjunct
therapi
cf
pex
act
smallmolecul
inhibitor
matrix
implic
cf
airway
pathophysiolog
particularli
pex
singlecent
rct
randomli
assign
cf
patient
pex
requir
inpati
care
either
doxycyclin
mg
oral
twice
daili
placebo
day
addit
standard
patient
care
iv
antibiot
increas
airway
clearanc
compar
placebo
group
doxycyclin
group
signific
decreas
total
activ
sputum
level
improv
proteaseantiproteas
imbal
airway
greater
improv
fev
predict
admiss
longer
time
next
pex
whether
doxycyclin
direct
effect
dysregul
proteas
activ
versu
indirect
effect
due
chang
microbiom
remain
unclear
singlecent
studi
set
stage
larger
multicent
placebocontrol
rct
although
system
corticosteroid
use
cf
exacerb
limit
evid
support
use
one
small
pilot
placebocontrol
studi
involv
patient
year
old
examin
oral
prednison
mgkg
per
day
maximum
mg
divid
twice
daili
versu
placebo
first
day
adjunct
standardofcar
pex
treatment
although
signific
effect
lung
function
symptom
improv
sputum
inflammatori
marker
compar
placebo
studi
underpow
evalu
treatment
effect
multicent
random
placebocontrol
trial
evalu
prednison
cf
pulmonari
exacerb
pipe
way
involv
six
pediatr
adult
cf
clinic
across
canada
studi
provid
definit
evid
regard
role
system
corticosteroid
pex
patient
receiv
iv
antibiot
treatment
respond
standard
care
alon
day
recov
least
baselin
fev
predict
randomli
assign
prednison
mgkg
per
day
maximum
mg
divid
twice
daili
placebo
day
field
cf
tremend
interest
identifi
biomark
could
aid
earlier
diagnosi
cf
pex
assist
track
respons
pex
treatment
earlier
diagnosi
allow
timeli
initi
treatment
might
result
better
pex
outcom
reliabl
biomark
respons
treatment
could
also
identifi
nonrespond
earlier
cours
treatment
therapi
modifi
extend
accordingli
major
biomark
relat
pex
focus
inflamm
sputum
blood
although
sputum
attract
option
close
reflect
airway
inflamm
evalu
limit
research
studi
challeng
collect
process
clinic
laboratori
sever
sputum
biomark
inflamm
includ
neutrophil
elastas
ne
calprotectin
club
cell
secretori
protein
ccsp
investig
pex
although
sputum
biomark
chang
significantli
stabl
pex
state
follow
pex
treatment
result
variabl
studi
sputum
ne
appear
promis
recent
studi
water
et
al
found
decreas
sputum
ne
independ
associ
respons
iv
antibiot
treatment
day
higher
ne
level
day
associ
greater
risk
subsequ
pex
among
blood
biomark
numer
marker
inflamm
evalu
recent
review
serum
creactiv
protein
crp
calprotectin
extens
studi
context
pex
offer
promis
clinic
use
studi
evalu
crp
calprotectin
cf
demonstr
signific
reduct
level
begin
end
pex
treatment
howev
recent
studi
demonstr
crp
increas
patient
first
day
iv
antibiot
treatment
prior
decreas
thu
make
challeng
biomark
monitor
earli
respons
treatment
individu
persist
elev
crp
calprotectin
level
follow
iv
antibiot
also
experi
shorter
time
reexacerb
although
sever
candid
biomark
correl
clinic
outcom
pex
treatment
identifi
remain
unclear
whether
prospect
use
influenc
treatment
decis
improv
pex
outcom
whether
add
increment
util
monitor
symptom
lung
function
alon
although
small
increment
progress
made
understand
pex
cf
basi
observ
studi
remain
sever
gap
knowledg
need
intervent
studi
guid
evidencebas
practic
cf
commun
eagerli
await
result
aforement
rct
evalu
variou
iv
antibiot
treatment
durat
adjunct
use
system
corticosteroid
doxycyclin
potenti
improv
pex
outcom
addit
greater
understand
sequenc
event
lead
pex
molecular
level
requir
improv
pex
phenotyp
guid
develop
target
treatment
